Navigation Links
Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting

Diversity of Abstracts Reflects Continued Growth of Eisai's Commitment to Oncology

WOODCLIFF LAKE, N.J., May 31, 2007 /PRNewswire/ -- Eisai announced today that several abstracts covering clinical data about their oncology pipeline compounds have been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from June 1-5, 2007.

These abstracts reveal a growing and diverse oncology clinical development program at Eisai. In addition to the variety of oncology product classes under investigation, these compounds are being studied in advanced diseases where there remains considerable unmet medical need, particularly in refractory metastatic breast cancer, advanced non-small cell lung cancer, and advanced ovarian cancer.

The following abstracts highlight data from pipeline compounds that have been accepted for presentation at this year's ASCO meeting.


    Product        Abstract Details                        Location Details


    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389) Halichondrin B Analog in        AM - 1:00 PM

    (E7389)        Patients with Refractory Breast Cancer  Location: S403

    Abstract No:   Poster Number: 21

    1034



    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389), a Mechanistically Novel        AM - 1:00 PM

    (E7389)        Inhibitor of Microtubule Dynamics,      Location: E451a

    Abstract No:   in Patients with Advanced Non-Small

    7546           Cell Lung Cancer (nsclc)

                   Poster Number: 20



    MORAb-003      Novel Phase II Study Design of          June 2, 2007

    Abstract No:   MORAb-003, a Monoclonal Antibody        2:00 PM - 6:00 PM

    5583           against Folate Receptor Alpha in        Location: S Hall A2

                   Platinum-Sensitive Ovarian Cancer

                   in First Relapse

    
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
(Date:3/4/2015)... March 4, 2015 Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that Pedro ... The Opening Bell ® of the New York ... began trading as an NYSE MKT listed company on ... Exchange is a trusted partner to Asterias Biotherapeutics, and ...
(Date:3/4/2015)... 2015 InfuSystem Holdings, Inc. (NYSE MKT: INFU), ... services for the U.S. healthcare industry, today announced that ... financial results on Monday, March 9, 2015 after the ... a conference call for investors on Monday, March 9, ... quarter and full year 2014 performance and results.  To ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
(Date:3/4/2015)... 04, 2015 With the growing influence of ... of our teens and young adults, combined with the increasingly ... confusing to try to keep up with what kids are ... trend is replaced on a daily basis. , The same ... the slang that is used to discreetly talk about them, ...
(Date:3/4/2015)... 04, 2015 More than a year ... potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), ... it will now require manufacturers to warn patients that ... heart attacks and strokes. In a Drug Safety ... stated that it was requiring testosterone manufacturers to update ...
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
(Date:3/4/2015)... 2015 The print component of “Organic ... Francisco Chronicle with a circulation of approximately 173,000 copies ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... is composed of heat-dried microbes that have digested the ...
(Date:3/4/2015)... Atlanta, Georgia (PRWEB) March 04, 2015 ... Georgia, part of the School of Public Health at ... , The funds were awarded by Georgia’s Division of ... contract to support the DFCS Call Center. , ... child maltreatment by providing information and referral services that ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... adults of industrialized countries is approximately 10% and is ... is scarce. , A research article published ... Gastroenterology addresses this problem. The team lead by Dr. ... Canada, has reviewed the rate of gallstone disease and ...
... means of microsatellite markers has become an effective way ... candidate tumor suppressor genes. In a previous study, it ... frequencies, which indicated that the region might harbor the ... contained so many genes that it was inconvenient to ...
... Intraductal papillary neoplasm of the bile duct (IPN-B) is ... is a new definition of a tumor with papillary ... authors reported a case of IPN-B with interesting histopathological ... the diagnosis of bile duct dilatation due to the ...
... ARNA ) today announced it will report first ... on Wednesday, May,7, 2008. That same afternoon, Jack Lief, ... Arena,s Vice President, Finance,and Chief Financial Officer, will host ... Pacific Time) to discuss the first quarter 2008,financial results ...
... 30 The following is an,editorial from The Wall ... Committee:, [J]ohn McCain delivered another speech yesterday on ... could lead to some of the most,constructive changes to ... for his candidacy if Mr. McCain is making space ...
... FRAZER, Pa., April 30 Cephalon, Inc. (Nasdaq:,CEPH) ... Executive Vice,President and General Counsel. In this position, ... company, including those relating to commercial,and financial transactions, ... directly to Chairman and CEO, Frank,Baldino Jr., Ph.D., ...
Cached Medicine News:Health News:A patient who was diagnosed as IPN-B without hepatolithiasis? 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 2Health News:Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008 3Health News:RNC: McCain's Progress 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 2Health News:Cephalon Appoints Gerald J. Pappert as General Counsel 3
AnkleWALKER™ Shorter uprights and circumferential plastic shell inhibit foot and ankle motion. Designed to provide comfortable stability for acute ankle sprains, soft tissue injuries, stress an...
... The FoamWalker is a cost-effective walking ... support. It has a lightweight, durable, semi-rigid ... protection. The shell's rocker sole helps reduce ... two aircells for compression and support at ...
... VACOPED is a revolutionary cast replacement ... the lower leg and foot. , ... patient's anatomy and in conjunction with a ... the general time of fracture or rupture ...
... of controlled compression and cold, the Calf ... anatomically designed cuff provides complete calf coverage ... as a single cuff, or with a ... disk). The Cooler is available separately and ...
Medicine Products: